Henry Schein, Inc. $HSIC Shares Sold by Nuance Investments LLC

Nuance Investments LLC reduced its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 61.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 314,208 shares of the company’s stock after selling 494,249 shares during the period. Henry Schein accounts for about 2.1% of Nuance Investments LLC’s holdings, making the stock its 17th biggest position. Nuance Investments LLC’s holdings in Henry Schein were worth $20,854,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Artisan Partners Limited Partnership raised its stake in Henry Schein by 0.9% during the 2nd quarter. Artisan Partners Limited Partnership now owns 6,462,204 shares of the company’s stock worth $472,064,000 after acquiring an additional 55,653 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in Henry Schein by 3,275.2% in the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after acquiring an additional 2,199,695 shares in the last quarter. Schroder Investment Management Group grew its holdings in shares of Henry Schein by 149.3% during the second quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock worth $114,243,000 after purchasing an additional 936,471 shares during the last quarter. M.D. Sass LLC increased its position in shares of Henry Schein by 21.3% during the third quarter. M.D. Sass LLC now owns 1,314,603 shares of the company’s stock worth $87,250,000 after purchasing an additional 230,407 shares in the last quarter. Finally, Swedbank AB lifted its holdings in shares of Henry Schein by 12.4% in the 3rd quarter. Swedbank AB now owns 1,299,571 shares of the company’s stock valued at $86,253,000 after purchasing an additional 143,173 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $79.72 on Monday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.40 and a quick ratio of 0.79. The firm has a market cap of $9.38 billion, a price-to-earnings ratio of 25.23, a price-to-earnings-growth ratio of 2.37 and a beta of 0.88. The firm’s fifty day moving average price is $76.40 and its 200 day moving average price is $70.98. Henry Schein, Inc. has a 1-year low of $60.56 and a 1-year high of $81.35.

Analysts Set New Price Targets

Several research firms have commented on HSIC. Evercore lifted their price target on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Mizuho set a $81.00 target price on shares of Henry Schein and gave the company a “neutral” rating in a report on Tuesday, January 20th. Barrington Research set a $79.00 price target on shares of Henry Schein and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $76.42.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.